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Some patients treated by chemotherapy for benign or malignant diseases are subsequently at risk for the development of a primary (Grunwald & Rosner 1979) or secondary malignancy (Chabner, 1977) .
Cytotoxic drugs can act as mutagens or carcinogens. Chromosome damage is recognised as being a sensitive biological indicator of exposure to physical or chemical mutagens/carcinogens (Wolff, 1982) and this genotoxic effect can be be measured in peripheral blood lymphocytes, bone marrow and other tissues. Our earlier study of patients during and shortly after receiving chemotherapy for a gestational trophoblastic tumour (GTT) showed that although very little chromosomal damage was observed with some of the regimes, intensive chemotherapy did have some effects (Lawler & Walden, 1978) . We now report a review and followup (at least 5 years after the chemotherapy ended) of some of the patients examined in our previous study and serial studies of a patient who had received ten courses of intensive chemotherapy more than 3 years previously.
Patients and methods
The patients were females aged between 21 and 37 years when treated at the Charing Cross Hospital, London. All but one of them had a GTT and the therapy was monitored by measuring levels of human chorionic gonadotrophin (HCG prognostic factors (Bagshawe, 1976 (Bagshawe, 1984) , was included in the study.
All the patients were well and in remission at the time of the follow-up chromosome studies.
Peripheral blood (PB) lymphocyte cultures were set up from heparinised whole blood as follows: 0.4mlPB, 8mlTC199, 2mlAB serum (1st study) or 2 ml foetal calf serum (2nd study), 0.1 ml phytohaemagglutinin (PHA) (Wellcome, Reagent grade). The cultures were incubated at 37°C and terminated at 48 or 72 h, following 1.5 h exposure to 2 ,ug ml-1 colcemid. In the first study the chromosomes were stained with Giemsa but were not banded. One hundred lymphocytes were scored for the presence (Q The Macmillan Press Ltd., 1985 of gaps, breaks, fragments and abnormal chromosomes. In the follow-up study the chromosomes were Giemsa-banded using a modification of the technique of Gallimore & Richardson (1973) . The cells were analysed and the chromosome abberations were scored using standard criteria (ISCN 1978) . For cell kinetic and sister-chromatid exchange (SCE) studies, cultures containing 2 pugml-1 5-bromo-2'-deoxyuridine were incubated in the dark, harvested and spread onto slides in the usual way. Cells were then stained using a modification of the FPG method of Perry & Wolff (1974) .
Results
The results of a review of the earlier studies of the unbanded chromosomes of the patients in the longterm follow-up investigation are given in Table I numerical changes were not found in our series of controls.
Six of the 9 natients in Table II and that they subsequently re-entered the circulating lymphocyte pool.
Although there was some variation between patients, more persistent chromosome damage was generally found within the medium and high-risk groups. Among our controls, the majority of abnormalities were simple breaks or gaps. However, in the patients, cells with deletions (or more complex structural abnormalities) and numerical changes contributed substantially to the numbers of abnormal cells; the most complex changes occurring in the two intensively-treated patients in the highrisk category (nos. 519 and 975).
For the measurement of chromosome damage it is preferable to examine cells in their first division in vitro. The majority of cells in 48 h cultures were in first division, but the percentage of cells in first division was lower at 72 h in all patients in whom cultures were made at both times. It is possible therefore, that some of the lesions observed when the culture time was extended to 72 h could have arisen in vitro.
Some chromosome changes are known to be important in the initiation or progression of malignancy. However, it is not yet clear how the presence of chromosome abnormalities in the lymphocytes of patients treated with cytotoxic agents for benign or malignant conditions, relates to the risk of developing a subsequent neoplasm. For example, when chlorambucil is used in continuous or intermittent schedules for the treatment of non-malignant disorders, there is an increased risk of the development of leukaemia (reviewed by Palmer et al., 1984) . Among a series of patients with uveitis treated with chlorambucil, we found some to have chromosome damage persisting for many years after the cessation of therapy (Reeves et al., submitted for publication) but there is as yet no case of malignancy recorded among them. Lambert et al. (1984) studied a group of 50 patients with ovarian carcinoma treated with melphalan, in some cases combined with radiotherapy, and found high levels of chromosome aberrations persisting for up to 8 years after treatment. Patients on this treatment protocol are known to be at risk of developing secondary leukaemia (Einhorn et al., 1982) . However, no case of leukaemia had been found by Lambert et al., although one patient (who had also received radiotherapy) developed a gastric carcinoma 5 years after completing therapy.
We have found evidence in this study for the persistence of genotoxic damage many years after the completion of successful chemotherapy. However, Rustin et al. (1983) have reported that patients treated for GTT do not have an increased risk of developing a subsequent malignancy at another site. The treatment protocols for GTTs are based on regular intermittent schedules over a mean period with no maintenance, and Rustin et al. have suggested that this method of giving therapy might be an important factor contributing to the lack of risk. However, it must also be borne in mind that these trophoblastic tumours are genetically foreign to the host, whereas in patients with tumours derived from host tissue, genetic susceptibility could account for or contribute to the occurrence of second tumours.
